Drug Profile
Litronesib
Alternative Names: KF 89617; LY 2523355Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Eli Lilly and Company; Kyowa Hakko
- Class Amides; Antineoplastics; Small molecules; Thiadiazoles
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Leukaemia; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 26 Apr 2013 Discontinued - Phase-I for Leukaemia (acute leukaemia) in USA (IV)
- 26 Apr 2013 Discontinued - Phase-I for Solid tumours (late-stage disease, metastatic disease) in Japan (IV)
- 26 Apr 2013 Discontinued - Phase-II for Breast cancer (metastatic disease) in USA (IV)